UK Supreme Court rules against Actavis in Eli Lilly patent dispute

07-07-2017

The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.


UK Supreme Court; Actavis; Eli Lilly; patent; Alimta; English Court of Appeal; pemetrexed

LSIPR